Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer

Table 2 Univariate and multivariate analysis of clinicopathological variables and keratin 80 expression associated with overall survival

Parameters	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	1.230 (0.682-2.216)	0.491
Age (< 60 years vs ≥ 60 years)	1.475 (0.834-2.609)	0.181
Tumor location (upper vs middle + lower)	0.827 (0.468-1.462)	0.514
Tumor size (< 6 cm vs ≥ 6 cm)	0.879 (0.501-1.544)	0.653
Differentiation (well + moderate vs poor + undifferentiated)	0.758 (0.432-1.330)	0.335
pT stage (T1-T2 vs T3-T4 )	1.047 (0.597-1.836)	0.872
Lymph node metastasis (absent vs present)	3.212 (1.155-8.938)	0.025	3.110 (1.117-8.657)	0.03
pTNM stage (I-II vs III-IV)	1.409 (0.703-2.842)	0.333
KRT80 expression (low vs high)	2.174 (1.169-4.044)	0.014	2.119 (1.139-3.943)	0.018

Gender: Men generally have worse outcomes than women due to later diagnosis and biological differences. Age: Older age worsens prognosis due to comorbidities and limited treatment options. Tumor location: Proximal tumors often have worse prognosis; distal tumors are more treatable. Tumor size: Larger tumors indicate more advanced disease and poorer prognosis. Differentiation: Poorly differentiated tumors are more aggressive and have worse outcomes. pT stage: Deeper tumor invasion correlates with worse prognosis and greater spread potential. Lymph node metastasis: Lymph node involvement worsens prognosis due to regional spread and higher recurrence risk. pTNM stage: Higher ptumor-node-metastasis stages predict worse prognosis, indicating advanced disease and lower survival rates; KRT80: Keratin 80; HR: Hazard ratio.